Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
    • AGM Invitations
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Egetis Therapeutics

5,37 SEK

+0,19 %

Mindre end 1K følgere

EGTX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Investorkonsensus
Sammenligne
+0,19 %
+8,27 %
+0,56 %
+4,27 %
+7,94 %
+31,94 %
+4,27 %
-6,80 %
-61,19 %

Egetis Therapeutics is a pharmaceutical company focused on developing innovative treatments for rare diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business has a global presence and serves customers worldwide. Egetis Therapeutics was founded in 2006 and is headquartered in Stockholm, Sweden.

Læs mere
Markedsværdi
2,28 mia. SEK
Aktieomsætning
2,15 mio. SEK
Omsætning
62,4 mio.
EBIT %
-544,71 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
29.4
2026

Delårsrapport Q1'26

6.5
2026

Generalforsamling '26

21.8
2026

Delårsrapport Q2'26

Alle
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelsefor 11 timer siden

NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)

Egetis Therapeutics
Pressemeddelelse9.3.2026, 06.00

Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S.

Egetis Therapeutics
Pressemeddelelse5.3.2026, 09.56

Redeye: Egetis Therapeutics (Q4 review): US approval on the horizon

Egetis Therapeutics

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse2.3.2026, 16.10

Egetis Therapeutics Launches Educational Websites on MCT8 Deficiency for Physicians and Caregivers

Egetis Therapeutics
Egetis Therapeutics, Audiocast, Q4'25
Videopræsentation26.2.2026, 09.00

Egetis Therapeutics, Audiocast, Q4'25

Egetis Therapeutics
Selskabsmeddelelse26.2.2026, 06.00

Year-End Report January-December 2025

Egetis Therapeutics
Pressemeddelelse24.2.2026, 10.00

Egetis Therapeutics to Present at Upcoming Investor Events

Egetis Therapeutics
Pressemeddelelse19.2.2026, 09.30

Invitation to presentation of Egetis’ fourth quarter and year-end 2025 report on February 26, 2026

Egetis Therapeutics
Pressemeddelelse16.2.2026, 06.00

Egetis provides update on progress with the development of Emcitate® (tiratricol) for MCT8 deficiency in Japan

Egetis Therapeutics
Pressemeddelelse4.2.2026, 14.25

FDA's rare pediatric disease priority review program extended until 2029

Egetis Therapeutics
Selskabsmeddelelse29.1.2026, 06.00

Egetis Completes the U.S. Rolling NDA Submission for Emcitate® (tiratricol) for Treatment of MCT8 Deficiency

Egetis Therapeutics
Pressemeddelelse16.1.2026, 11.45

Chairman of the Board of Egetis Therapeutics acquires shares

Egetis Therapeutics
Pressemeddelelse8.1.2026, 08.30

Egetis Therapeutics to Host Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

Egetis Therapeutics
Selskabsmeddelelse30.12.2025, 07.00

Change in the number of ordinary shares and votes in Egetis Therapeutics

Egetis Therapeutics
Selskabsmeddelelse19.12.2025, 06.00

Egetis Therapeutics initiates New Drug Application in the USA for Emcitate® (tiratricol) for MCT8 deficiency

Egetis Therapeutics
Pressemeddelelse17.12.2025, 12.35

Egetis Therapeutics to move to the Nasdaq Stockholm Mid Cap segment

Egetis Therapeutics
Pressemeddelelse10.12.2025, 06.00

Egetis and Er-Kim Expand Partnership to Broaden Access to Emcitate® Across Central, Eastern, and Southeastern Europe

Egetis Therapeutics
Pressemeddelelse4.12.2025, 09.55

New publication highlights meaningful clinical benefits of Emcitate® (tiratricol) in treating Resistance to Thyroid Hormone Beta

Egetis Therapeutics
Pressemeddelelse1.12.2025, 10.15

Members of Egetis' Leadership Team acquire shares in Egetis

Egetis Therapeutics
Pressemeddelelse27.11.2025, 13.07

Redeye: Egetis (Q3 review) - Focus on US application

Egetis Therapeutics
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.